Relationship between stress hyperglycemia ratio and allcause mortality in critically ill patients: Results from the MIMIC-IV database

Chong Zhang[1,2,3,4,5†], He-Chen Shen[1,2,3,4,5†], Wei-Ru Liang[6†], Meng Ning[2,3,4,5†], Zi-Xuan Wang[1,2,3,4], Yi Chen[1,2,3,4,5], Wei Su[1,2,3,4,5], Ting-Ting Guo[1,2,3,4,5], Kun Hu[1,2,3,4,5] and Ying-Wu Liu[1,2,3,4,5*]

[1]The Third Central Clinical College of Tianjin Medical University, Tianjin, China, [2]Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, The Third Central Hospital of Tianjin, Tianjin, China, [3]Artificial Cell Engineering Technology Research Center, The Third Central Hospital of Tianjin, Tianjin, China, [4]Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China, [5]Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin, China, [6]State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background: Stress hyperglycemia ratio (SHR) was developed to reduce the impact of long-term chronic glycemic factors on stress hyperglycemia levels, which have been linked to clinical adverse events. However, the relationship between SHR and the short- and long-term prognoses of intensive care unit (ICU) patients remains unclear.

Methods: We retrospectively analyzed 3,887 ICU patients (cohort 1) whose initial fasting blood glucose and hemoglobin A1c data within 24 hours of admission were available and 3,636 ICU patients (cohort 2) who were followed-up for 1-year using the Medical Information Mart for Intensive Care IV v2.0 database. Patients were divided into two groups based on the optimal cutoff value of SHR, which was determined using the receiver operating characteristic (ROC) curve.

Results: There were 176 ICU deaths in cohort 1 and 378 patients experienced all-cause mortality during 1 year of follow-up in cohort 2. The results of logistic regression revealed that SHR was associated with ICU death (odds ratio 2.92 [95% confidence interval 2.14−3.97] *P* < 0.001), and non-diabetic patients rather than diabetic patients showed an increased risk of ICU death. As per the Cox proportional hazards model, the high SHR group experienced a higher incidence of 1-year all-cause mortality (hazard ratio 1.55 [95% confidence interval 1.26−1.90] *P* < 0.001). Moreover, SHR had an incremental effect on various illness scores in predicting ICU all-cause mortality.

Conclusion: SHR is linked to ICU death and 1-year all-cause mortality in critically ill patients, and it has an incremental predictive value in different illness scores. Moreover, we found that non-diabetic patients, rather than diabetic patients, showed an increased risk of all-cause mortality.

Introduction

Patients suffering from trauma and critical illness often experience stress-induced hyperglycemia (SIH), even if they have no history of diabetes, leading to insulin resistance (IR) due to acute stress, inflammatory reaction, and severe disruption in glucose metabolism. Their glucose levels are often above average. During the period of sympathetic overactivity, catecholamine inhibits insulin release and promotes glycogen decomposition, which reduces the glucose uptake of the heart and leads to overactivity of hyperglycemia related proinflammatory pathway (1, 2). In acute myocardial infarction (AMI) patients, the SIH is a cause of over-inflammation and myocardial scar extension, which could over-activate inflammatory and fibrotic pathways with consequent worse clinical outcomes (3). Previous studies have demonstrated gut and thrombus microbiota dysbiosis and the miR33/sirtuin 1 pathway increased pro-inflammatory and pro-coagulable state of coronary thrombi, and thrombus aspiration could reduce clinical outcomes in AMI patients with SIH (4–6). Up to now, numerous studies have demonstrated that SIH is associated with adverse outcomes in the intensive care unit (ICU) for critically ill patients (1, 7–11).

However, in the absence of evidence, the glucose level was chosen arbitrarily. Therefore, the definition of the optimal cut-off value of SIH is inconsistent among guidelines. The European Society of Cardiology (ESC) recommends that SIH be defined as an admission blood glucose level higher than 11 mmol/L, whereas the American Heart Association (AHA) recommends that SIH be defined as an admission blood glucose level higher than 10 mmol/L, irrespective of diabetes diagnosis (12, 13). Currently, the optimal threshold of SIH and its association with the prognosis of ICU patients remain unclear and need to be addressed urgently.

In addition, it is necessary to include diabetic patients to comprehensively evaluate the prognosis of SIH in ICU patients. The results of a previous study were inconclusive about the prognostic value of SIH in diabetic patients (1), which suggests that SIH may not be a reliable risk factor in some special cases. To avoid misestimating the true prevalence of stress hyperglycemia, the stress hyperglycemia ratio (SHR) was developed to reduce the impact of long-term chronic glycemic factors on stress hyperglycemia levels (14). Moreover, previous studies mainly focused on SHR and clinical adverse outcomes in AMI, whereas few studies focused on ICU patients.

In this study, we evaluated the cut-off values of SHR in predicting ICU all-cause mortality and 1-year all-cause mortality in critically ill patients. In addition, we included SHR in evaluating the predictive value of various risk scores.

Methods

Study population

This is a retrospective study, and data were extracted from the Medical Information Mart for Intensive Care IV v2.0 (MIMIC-IV-v2.0) database. MIMIC-IV-v2.0 is a single-center database that was updated based on MIMIC-IV-v1.0. It was released on June 12, 2022 and is maintained by the Massachusetts Institute of Technology (MIT). The database contains medical data from Beth Israel Deaconess Medical Center (Boston, Massachusetts, USA) from 2008 to 2019. One of the authors (Hechen Shen) is authorized to use the database (Record ID 49784899).

We included 19,328 patients in our analysis. Patients admitted to the ICU for the first time and aged ≥ 18 years were included. The exclusion criteria included: (1) patients aged < 18 years; (2) patients whose HbA1c or fasting blood glucose data within 24 hours of admission were unavailable; and (3) patients who were discharged or died within 24 hours in the ICU. Finally, a total of 3,887 patients were included in the cohort (cohort 1) and divided into two groups according to the cutoff values for SHR. Moreover, 3,636 patients who were discharged from the hospital were followed up for 1 year (cohort 2). The flow chart is shown in Figure 1.

Study variables

Data related to hospitalization within 24 hours of ICU admission were extracted from the MIMIC-IV-v2.0 database using PostgreSQL (version 14.5) and Navicat Premium (version 15.0) software. The data included the following variables: body mass index (BMI), gender, age, first ICU type, heart rate, diastolic blood pressure (DBP), systolic blood pressure (SBP), pulse blood oxygen saturation (SPO$_2$), hemoglobin, white blood cells, platelets, glucose, hemoglobin a1c (HbA1c), creatinine, sequential organ failure assessment (SOFA) score, systemic inflammatory response syndrome (SIRS) score, logistic organ dysfunction system (LODS)

FIGURE 1
Flow chart of the study. ICU, intensive care unit.

score, acute physiology score III (APS III), model for end-stage liver disease (MELD), and oxford acute severity score (OASIS). SHR was calculated as [(admission glucose (mg/dl))/(28.7×HbA1c (%)-46.7)] [14]. Comorbidities refer to coronary heart disease, hypertension, diabetes, chronic obstructive pulmonary disease (COPD), and chronic kidney disease (CKD), prediabetes. The diagnosis of comorbidities was determined based on the discharge diagnosis according to the documented International Classification of Diseases, version 9 (ICD-9) codes and International Classification of Diseases, version 10 (ICD-10) codes.

Adverse clinical events

The primary outcomes included ICU all-cause mortality and 1-year all-cause mortality. The secondary outcomes included length of stay (LOS) in the ICU. Survival time is determined by date of death in the MIMIC-IV-v2.0 database.

Statistical analysis

Patients in the two cohorts were divided into two groups based on the optimal cut-off value of SHR (< 1.10 or ≥ 1.10) and the optimal cutoff value of SHR (< 1.18 or ≥ 1.18), respectively, which was calculated using the receiver operating characteristic (ROC) curve. Continuous variables with a normal distribution are expressed as mean ± standard deviation (SD). Nonparametric continuous variables are expressed as the medians and interquartile ranges (25th–75th). Categorical variables are expressed as frequencies and percentages. The unpaired t test, Mann–Whitney U test, and chi-square test were used to test for

differences between groups for continuous and categorical variables. Multivariate imputation (MI) was used to handle missing values less than 30%. Covariates that have been demonstrated the traditional risk factors for mortality were used for the adjustment model included age, gender, hypertension, diabetes, COPD, and CKD. Logistic regression, multiple linear regression, and sensitivity analysis were used to estimate the ICU adverse outcomes associated with SHR in cohort 1. By adding SHR to the severity of the illness scores (SIRS score, SOFA score, MELD score, APSIII score, LODS score, OASIS score), the area under the curve (AUC) was used to assess the accuracy of predicting ICU all-cause mortality. Kaplan–Meier survival analysis and Cox proportional hazards models were used to estimate the 1-year percentage of cumulative survival in cohort 2. We used the Cox proportional hazards models to estimate the relationship between SHR and 1-year all-cause mortality among subgroups. We used Stata 17.0 (Stata Corp, College Station, TX) for all analyses. A two-tailed P value < 0.05 was considered statistically significant.

Results

Baseline characteristics

Finally, 3,887 ICU patients were included in cohort 1 and 3,636 patients who were followed up for 1 year after discharge from the hospital were included in cohort 2. There were 176 patients who experienced ICU death and 251 patients who experienced in-hospital all-cause mortality. During the 1-year follow-up, 378 patients experienced all-cause mortality. The optimal cut-off value of SHR to predict ICU all-cause mortality was 1.23 (sensitivity 0.59, specificity 0.68, Youden's index = 0.27, AUC=0.63) and that to

predict 1-year all-cause mortality was 1.18 (sensitivity 0.47, specificity 0.65, Youden's index = 0.12, AUC=0.56). Patients in the high SHR group were more likely to have higher glucose levels, higher severity of illness scores, suffer from hypertension, prolonged ICU LOS, and a higher incidence of ICU all-cause mortality compared with the low SHR group (Table 1). As shown in Table

S1, patients in the high SHR group were more likely to have higher severity of illness scores, higher glucose levels, higher HbA1c levels, comorbidities, and a higher incidence of 1-year all-cause mortality. Although prediabetes leads to coronary endothelial dysfunction (15), there were no difference in prediabetes patients between the two groups among cohort 1 and cohort 2 in this study.

TABLE 1 Baseline characteristics and events of cohort 1.

Categories	Low SHR n=2604	High SHR n=1283	P value
Demographic			
Age, year	63.3 ± 14.8	63.1 ± 14.5	0.62
Sex, male, n (%)	1563 (60.0)	709 (55.3)	0.005
Body mass index, kg/m^2	28.4 ± 5.3	28.4 ± 5.6	0.75
Comorbidities			
CHD, n (%)	1142 (43.9)	428 (33.4)	<0.001
CKD, n (%)	500 (19.2)	284 (22.1)	0.032
COPD, n (%)	32 (1.2)	27 (2.1)	0.036
Hypertension, n (%)	804 (30.9)	306 (23.9)	<0.001
Prediabetes, n (%)	29 (1.1)	9 (0.7)	0.22
Diabetes, n (%)	1073 (41.2)	607 (47.3)	<0.001
Laboratory tests			
Creatinine, μmol/L	0.9 (0.7, 1.3)	1.1 (0.8, 1.6)	<0.001
Glucose, mmol/L	115.0 (99.0, 133.0)	189.0 (156.0, 255.0)	<0.001
HbA1c	5.9 (5.5, 6.8)	5.8 (5.3, 6.6)	<0.001
LDL, mg/dL	81.0 (72.0, 93.0)	81.0 (73.0, 82.0)	0.016
ALT, U/L	27.0 (25.0, 27.0)	27.0 (24.0, 46.0)	<0.001
AST, U/L	38.0 (33.0, 38.0)	38.0 (35.0, 72.0)	<0.001
HGB, mg/dL	11.5 (10.0, 13.1)	11.5 (9.8, 13.3)	0.72
Plt, K/μL	210.0 (159.0, 270.0)	216.0 (163.0, 281.0)	0.055
WBC, K/μL	12.2 (9.0, 16.7)	13.7 (9.9, 18.1)	<0.001
ICU admission			
OASIS score	31.0 (25.0, 37.0)	34.0 (27.0, 41.0)	<0.001
LODS score	4.0 (2.0, 6.0)	5.0 (3.0, 8.0)	<0.001
APSIII score	40.0 (29.0, 54.0)	49.0 (35.0, 68.0)	<0.001
SIRS score	2.0 (2.0, 3.0)	3.0 (2.0, 3.0)	<0.001
SOFA score	3.0 (1.0, 5.0)	3.0 (2.0, 6.0)	<0.001
MELD score	11.0 (8.0, 17.0)	13.0 (9.0, 20.9)	<0.001
First Care Unit			<0.001
CVICU	901 (34.6)	207 (16.1)	
CCU	383 (14.7)	250 (19.5)	
MICU/SICU	919 (35.3)	623 (48.6)	
NSICU	207 (7.9)	77 (6.0)	

(Continued)

TABLE 1 Continued

Categories	Low SHR n=2604	High SHR n=1283	*P* value
TSICU	194 (7.5)	126 (9.8)	
Vital signs			
Heart rate, bmp	82.0 (71.0, 93.0)	84.0 (73.0, 96.0)	<0.001
SBP, mmHg	118.0 (111.0, 125.0)	118.0 (113.0, 126.0)	0.25
DBP, mmHg	61.0 (57.0, 65.0)	61.0 (57.0, 65.0)	0.99
SpO$_2$, %	97.0 (96.0, 98.0)	97.0 (96.0, 98.0)	0.67
Events			
LOS ICU, days	2.7 (1.6, 5.1)	3.9 (2.1, 7.6)	<0.001
ICU death, n (%)	74 (2.8)	102 (8.0)	<0.001

SHR, stress hyperglycemia ratio; CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HbA1c, hemoglobin a1c; LDL, low density lipoprotein; ALT, alanine transaminase; AST, aspartate aminotransferase; HGB, hemoglobin; WBC, white blood cell; ICU, intensive care unit; SOFA, sequential organ failure assessment; LODS, logistic organ dysfunction system; SIRS, systemic inflammatory response syndrome; OASIS, Oxford acute severity score; APS III, acute physiology score III; MELD, model for end-stage liver disease; CCU, coronary care unit; CVICU, cardiovascular intensive care unit; MICU/SICU, medical intensive care unit/surgical intensive care unit; TSICU, trauma/surgical intensive care unit; NSICU, neurosurgical intensive care unit.

Association between ICU prognosis and SHR

Logistic regression revealed the association between SHR (≥ 1.23) and ICU death both in the crude model (odds ratio [OR] 2.95 [95% confidence interval (CI) 2.17–4.01] P < 0.001) and the adjusted model (OR 2.92 [95% CI 2.14–3.97] *P* < 0.001). In sensitivity analysis, non-diabetic patients rather than diabetic patients showed an increased risk of ICU death (Table 2). In addition, the multiple linear regression model showed SHR was found as a significant predictor of ICU LOS (Table S2).

Association between SHR and 1-year all-cause mortality

Cox proportional hazards models showed a significant association between SHR (≥ 1.18) and 1-year all-cause mortality both in the crude

model (hazard ratio [HR] 1.59 [95% CI 1.30–1.94] P < 0.001) and the adjusted model (HR 1.55 [95% CI 1.26–1.90] *P* < 0.001). Kaplan–Meier survival analysis and Cox proportional hazards models revealed that the high SHR group had a higher incidence of 1-year all-cause mortality than the low SHR group (Figure 2). In addition, we estimated the relationship between SHR (≥ 1.18) and 1-year all-cause mortality among subgroups, including BMI, age, gender, diabetes, and hypertension. SHR was associated with increased risk of 1-year all-cause mortality in the subgroups of age < 65 years [HR 1.63 (95% CI 1.15–2.31)], male [HR 1.67 (95% CI 1.28–2.19)], BMI ≥ 30 kg/m^2 [HR 1.60 (95% CI 1.09–2.37)], hypertension [HR 1.84 (95% CI 1.16–2.90)], and non-diabetic [HR 1.60 (95% CI 1.21–2.11)] (Figure 3).

Incremental effect of SHR on ICU death

SHR had an incremental effect on the AUC of various illness scores in predicting ICU death, including SIRS score (0.639 vs.

TABLE 2 Association between the ICU death and SHR.

Categories	Crude model		Adjust model	
	OR and 95%CI	*P* value	OR and 95%CI	*P* value
ICU death				
Low SHR	Ref.		Ref.	
High SHR	2.95 (2.17 to 4.01)	<0.001	2.92 (2.14 to 3.97)	<0.001
ICU death (diabetic patients)				
Low SHR	Ref.		Ref.	
High SHR	1.87 (1.14 to 3.07)	0.014	1.80 (1.09 to 2.97)	0.021
ICU death (non-diabetic patients)				
Low SHR	Ref.		Ref.	
High SHR	4.03 (2.71 to 5.98)	<0.001	3.90 (2.62 to 5.80)	<0.001

SHR, stress hyperglycemia ratio; ICU, intensive care unit; OR, odds ratio; CI, confidence interval.

FIGURE 2
Association between the 1-year all-cause mortality and SHR **(A)** Kaplan-Meier survival analysis curves for all-cause mortality according to low SHR group and high SHR group at 1 year; **(B)** Survival curves according to low SHR group and high SHR group in the Cox proportional hazards model after adjustment for age, gender, hypertension, diabetes, COPD, and CKD. SHR, stress hyperglycemia ratio; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney diseases.


	Total (n=3636)	Low SHR (n=2315)	High SHR (n=1321)	HR and 95%CI	
Age			Favor high SHR	Favor low SHR	P_{int}=0.865
<65	1860 (51.2)	1147 (61.7)	713 (38.3)		1.63 (1.15 to 2.31)
≥65	1776 (48.8)	1168 (65.8)	608 (34.2)		1.55 (1.20 to 2.00)
Gender					P_{int}=0.482
Female	1506 (41.4)	915 (60.8)	591 (39.2)		1.44 (1.05 to 1.96)
Male	2130 (58.6)	1400 (65.7)	730 (34.3)		1.67 (1.28 to 2.19)
BMI					P_{int}=0.612
Low BMI	2325 (63.9)	1483 (63.8)	842 (36.2)		1.50 (1.18 to 1.91)
High BMI	1311 (36.1)	832 (63.5)	479 (36.5)		1.60 (1.09 to 2.37)
Hypertension					P_{int}=0.454
No	2570 (70.7)	1581 (61.5)	989 (38.5)		1.50 (1.19 to 1.88)
Yes	1066 (29.3)	734 (68.9)	332 (31.1)		1.84 (1.16 to 2.90)
Diabetes					P_{int}=0.747
No	2054 (56.5)	1345 (65.5)	709 (34.5)		1.60 (1.21 to 2.11)
Yes	1582 (43.5)	970 (61.3)	612 (38.7)		1.54 (1.14 to 2.08)

FIGURE 3
Forest plots of hazard ratios for the 1-year all-cause mortality in different subgroups. HR, hazard ratio; CI, confidence interval; SHR, stress hyperglycemia ratio; BMI, body mass index.

0.689, $P < 0.001$), SOFA score (0.688 vs. 0.719, $P = 0.004$), MELD score (0.600 vs. 0.686, $P < 0.001$), APSIII score (0.788 vs. 0.804, $P = 0.004$), LODS score (0.781 vs. 0.802, $P = 0.001$), and OASIS score (0.788 vs. 0.801, $P = 0.016$) (Table 3).

Discussion

In this study, we explored the relationship between SHR and ICU patients prognosis and found that high SHR was associated with ICU death and long-term all-cause mortality. The cut-off values of SHR in predicting ICU death and 1-year all-cause mortality were 1.23 and 1.18, respectively. Moreover, we found an

incremental effect of SHR as a novel and efficient biomarker for various illness scores in predicting ICU all-cause mortality.

Numerous studies have shown that ICU patients with SIH have an increased risk of worsening clinical outcomes (1, 7–11). SIH usually occurs in ICU patients and increases evidently within 48 hours in at least 50% of patients (16). SIH can increase IR and glucose levels in the body, which can cause the release of catecholamines, cortisol, glucagon, and growth hormones, promoting inflammation (2). In addition, ICU patients are often on parenteral nutrition with increased fat content, hyperglycaemia and inflammatory cytokines, such as interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), NAPDH oxidase-2 (NOX2) and NAPDH oxidase-1 (NOX1), which disrupts the body's metabolic

TABLE 3 Incremental effect of SHR in predicting ICU all-cause death.

Categories	Model 1	Model 2	P value (Model 2 vs. Model 1)
	AUC and 95%CI	AUC and 95%CI	
ICU death			
SIRS Score	0.639 (0.600 to 0.678)	0.689 (0.647 to 0.730)	<0.001
SOFA Score	0.688 (0.646 to 0.730)	0.719 (0.678 to 0.760)	0.003
MELD Score	0.600 (0.558 to 0.643)	0.686 (0.649 to 0.724)	<0.001
APSIII Score	0.788 (0.754 to 0.821)	0.804 (0.773 to 0.836)	0.004
LODS Score	0.781 (0.744 to 0.818)	0.802 (0.768 to 0.836)	0.001
OASIS Score	0.788 (0.759 to 0.816)	0.801 (0.772 to 0.829)	0.016

SHR, stress hyperglycemia ratio; ICU, intensive care unit; SOFA, sequential organ failure assessment; LODS, logistic organ dysfunction system; SIRS, systemic inflammatory response syndrome; OASIS, Oxford acute severity score; APS III, acute physiology score III; MELD, model for end-stage liver disease; AUC, area under the curve; CI, confidence interval; Model 1, various illness scores; Model 2, various illness scores+SHR.

pathways and leads to worsening clinical outcomes (17–19). Studies have found that SIH is associated with ICU death. Mamtani et al. (20) showed SIH was related to ICU death and a longer length of ICU stay in 739,152 non-diabetic patients. Rau et al. (21) included patients with trauma and found SIH was associated with a higher injury severity score. SHR can eliminate the interference of long-term chronic glycemic factors on stress hyperglycemia levels, which can reflect the stress response in the body. Previous studies found that SHR had a prognostic value in AMI (1, 22, 23) and acute ischemic stroke patients (24, 25). However, there are few studies focused on ICU patients. Our study further provides clinical evidence to support the notion that SHR is associated with adverse events in ICU patients.

Moreover, SHR had an incremental effect on the predictive value of various illness scores in predicting ICU all-cause mortality. These illness scores have been demonstrated to have a predictive value in predicting adverse outcomes in ICU patients (26–29). Considering that SHR is essential to the prognosis of ICU patients and is an easily available, reliable, and inexpensive test, we innovatively added SHR to various illness scores and found the predictive value for ICU all-cause death was significantly improved.

Notably, in the subgroup analysis, we also compared the association between SHR and 1-year all-cause mortality under various risk factor stratifications. Specifically, we found that non-diabetic patients had a higher risk of 1-year all-cause mortality than diabetic patients, which is consistent with the ICU deaths among non-diabetic patients and diabetic patients in the sensitivity analysis. Current studies have demonstrated that non-diabetic patients, rather than diabetic patients, have a higher risk of adverse events (21, 30). We consider the following mechanisms to explain this finding: Firstly, diabetes is an inflammatory clinical entity with different mechanisms involved in its physiopathology (31). However, in the course of diabetes, diabetic patients are adapted to chronic oxidative stress and consistently higher hyperglycemia levels than non-diabetic patients. Moreover, diabetic patients who have been treated with insulin, which has a better anti-inflammatory effect (32–34).

Our study demonstrated the translational potential role of SHR in predicting ICU death and 1-year all-cause mortality in critically ill patients. However, there are several limitations to this study. Firstly, this was an observational study. Although we utilized careful and rigorous statistical methods to control for bias, further studies should be performed to explore the relationship between SHR and the prognosis of ICU patients. Secondly, the data was derived from the United States, where people have different physical conditions and lifestyles from the East Asian population. Thirdly, due to patients' previous medical information about previous myocardial infarction, history of percutaneous coronary intervention (PCI), history of coronary artery bypass grafting (CABG) and pre-hospital medication, that cannot be obtained from the MIMIC-IV-v2.0 database, we cannot effectively address this bias. Prospective studies are needed to further investigate the effect of this bias on clinical outcomes.

Conclusions

SHR has translational potential in predicting ICU all-cause mortality and 1-year all-cause mortality in critically ill patients, with incremental predictive value in various illness scores. Moreover, we found that non-diabetic patients, rather than diabetic patients, had a higher risk of ICU all-cause mortality and 1-year all-cause mortality.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

All procedures performed in studies involving human participants were in accordance with the ethical standards of the

institutional and/or national research committee and with the 1964 Helsinki declaration. The use of the MIMIC-IV-v2.0 database was approved by the review committee of Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center. The data is publicly available (in theMIMIC-IV-v2.0 database) hence ethical approval statement and the informed consent is not required for the study.

Author contributions

Conception and design of the research: CZ, H-CS, W-RL, Y-WL, MN. Acquisition of data: H-CS, W-RL. Analysis and interpretation of the data: CZ, H-CS, W-RL, Z-XW, MN, YC, WS, T-TG, KH, Y-WL. Statistical analysis: CZ, H-CS, W-RL, Z-XW, YC, WS, T-TG, KH. Obtaining financing: Y-WL. Writing of the manuscript: CZ, H-CS, W-RL, Z-XW. Critical revision of the manuscript for intellectual content: MN, YC, WS, T-TG, KH, Y-WL. Moreover, CZ, H-CS, W-RL, MN have contributed equally to this work. All authors read and approved the final draft.

Funding

Acknowledgments

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2023.1111026/full#supplementary-material

SUPPLEMENTARY TABLE 1
Baseline characteristics and events of cohort 2. SHR, stress hyperglycemia ratio; CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HbA1c, hemoglobin a1c; LDL, low density lipoprotein; ALT, alanine transaminase; AST, aspartate aminotransferase; HGB, hemoglobin; WBC, white blood cell; ICU, intensive care unit; SOFA, sequential organ failure assessment; LODS, logistic organ dysfunction system; SIRS, systemic inflammatory response syndrome; OASIS, Oxford acute severity score; APS III, acute physiology score III; MELD, model for end-stage liver disease; CCU, coronary care unit; CVICU, cardiovascular intensive care unit; MICU/SICU, medical intensive care unit/surgical intensive care unit; TSICU, trauma/surgical intensive care unit; NSICU, neurosurgical intensive care unit.

SUPPLEMENTARY TABLE 2
The association between SHR and ICU LOS. SHR, stress hyperglycemia ratio; LOS, length of stay; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; Adjustment model included age, gender, hypertension, diabetes, COPD, CKD.

References

1. Sia CH, Chan MH, Zheng H, Ko J, Ho AF, Chong J, et al. Optimal glucose, HbA1c, glucose-HbA1c ratio and stress-hyperglycaemia ratio cut-off values for predicting 1-year mortality in diabetic and non-diabetic acute myocardial infarction patients. *Cardiovasc Diabetol* (2021) 20(1):211. doi: 10.1186/s12933-021-01395-3

2. Paolisso P, Bergamaschi L, Rambaldi P, Gatta G, Foà A, Angeli F, et al. Impact of admission hyperglycemia on heart failure events and mortality in patients with takotsubo syndrome at long-term follow-up: Data from HIGH-GLUCOTAKO investigators. *Diabetes Care* (2021) 44(9):2158–61. doi: 10.2337/dc21-0433

3. Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: A multicenter international registry. *Cardiovasc Diabetol* (2022) 21(1):77. doi: 10.1186/s12933-022-01506-8

4. D'Onofrio N, Sardu C, Paolisso P, Minicucci F, Gragnano F, Ferraraccio F, et al. MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients. *J Cell Physiol* (2020) 235(2):1438–52. doi: 10.1002/jcp.29064

5. Sardu C, Barbieri M, Balestrieri ML, Siniscalchi M, Paolisso P, Calabrò P, et al. Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: Clinical outcomes at 1-year follow-up. *Cardiovasc Diabetol* (2018) 17(1):152. doi: 10.1186/s12933-018-0795-8

6. Sardu C, Consiglia Trotta M, Santella B, D'Onofrio N, Barbieri M, Rizzo MR, et al. Microbiota thrombus colonization may influence athero-thrombosis in hyperglycemic patients with ST segment elevation myocardialinfarction (STEMI). marianella study. *Diabetes Res Clin Pract* (2021) 173:108670. doi: 10.1016/j.diabres.2021.108670

7. Cai S, Wang Q, Ma C, Chen J, Wei Y, Zhang L, et al. Association between glucose-to-lymphocyte ratio and in-hospital mortality in intensive care patients with sepsis: A retrospective observational study based on medical information mart for intensive care IV. *Front Med (Lausanne)* (2022) 9:922280. doi: 10.3389/fmed.2022.922280

8. Li M, Chen G, Feng Y, He X. Stress induced hyperglycemia in the context of acute coronary syndrome: Definitions, interventions, and underlying mechanisms. *Front Cardiovasc Med* (2021) 8:676892. doi: 10.3389/fcvm.2021.676892

9. Lee TF, Drake SM, Roberts GW, Bersten A, Stranks SN, Heilbronn LK, et al. Relative hyperglycemia is an independent determinant of in-hospital mortality in patients with critical illness. *Crit Care Med* (2020) 48(2):e115–22. doi: 10.1097/CCM.0000000000004133

10. Van Ackerbroeck S, Schepens T, Janssens K, Jorens PG, Verbrugghe W, Collet S, et al. Incidence and predisposing factors for the development of disturbed glucose metabolism and DIabetes mellitus AFter intensive care admission: the DIAFIC study. *Crit Care* (2015) 19:355. doi: 10.1186/s13054-015-1064-9

11. Kaukonen KM, Bailey M, Egi M, Orford N, Glassford NJ, Marik PE, et al. Stress hyperlactatemia modifies the relationship between stress hyperglycemia and outcome: A retrospective observational study. *Crit Care Med* (2014) 42(6):1379–85. doi: 10.1097/CCM.0000000000000214

12. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European society of cardiology (ESC). *Eur Heart J* (2017) 39(2):119–77. doi: 10.1093/eurheartj/ehx393

13. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American college of cardiology Foundation/American heart association task force on practice guidelines. *Circulation* (2013) 127(4):e362–425. doi: 10.1161/CIR.0b013e3182742cf6

14. Roberts GW, Quinn SJ, Valentine N, Alhawassi T, O'Dea H, Stranks SN, et al. Relative hyperglycemia, a marker of critical illness: Introducing the stress hyperglycemia ratio. *J Clin Endocrinol Metab* (2015) 100(12):4490–7. doi: 10.1210/jc.2015-2660

15. Sardu C, Paolisso P, Sacra C, Mauro C, Minicucci F, Portoghese M, et al. Effects of metformin therapy on coronary endothelial dysfunction in patients with prediabetes with stable angina and nonobstructive coronary artery stenosis: The CODYCE multicenter prospective study. *Diabetes Care* (2019) 42(10):1946–55. doi: 10.2337/dc18-2356

16. Plummer MP, Bellomo R, Cousins CE, Annink CE, Sundararajan K, Reddi BA, et al. Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality. *Intensive Care Med* (2014) 40(7):973–80. doi: 10.1007/s00134-014-3287-7

17. Caturano A, Galiero R, Pafundi PC, Cesaro A, Vetrano E, Palmiero G, et al. Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence. *Diabetes Res Clin Pract* (2021) 178:108959. doi: 10.1016/j.diabres.2021.108959

18. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. *Crit Care Clin* (2001) 17(1):107–24. doi: 10.1016/S0749-0704(05)70154-8

19. Esposito K, Ciotola M, Sasso FC, Cozzolino D, Saccomanno F, Assaloni R, et al. Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: Role of tumor necrosis factor-alpha. *Nutr Metab Cardiovasc Dis* (2007) 17(4):274–9. doi: 10.1016/j.numecd.2005.11.014

20. Mamtani M, Kulkarni H, Bihari S, Prakash S, Chavan S, Huckson S, et al. Degree of hyperglycemia independently associates with hospital mortality and length of stay in critically ill, nondiabetic patients: Results from the ANZICS CORE binational registry. *J Crit Care* (2020) 55:149–56. doi: 10.1016/j.jcrc.2019.11.003

21. Rau CS, Wu SC, Chen YC, Chien PC, Hsieh HY, Kuo PJ, et al. Higher mortality in trauma patients is associated with stress-induced hyperglycemia, but not diabetic hyperglycemia: A cross-sectional analysis based on a propensity-score matching approach. *Int J Environ Res Public Health* (2017) 14(10):1161. doi: 10.3390/ijerph14101161

22. Schmitz T, Freuer D, Harmel E, Heier M, Peters A, Linseisen J, et al. Prognostic value of stress hyperglycemia ratio on short- and long-term mortality after acute myocardial infarction. *Acta Diabetol* (2022) 59(8):1019–29. doi: 10.1007/s00592-022-01893-0

23. Chen G, Li M, Wen X, Wang R, Zhou Y, Xue L, et al. Association between stress hyperglycemia ratio and in-hospital outcomes in elderly patients with acute myocardial infarction. *Front Cardiovasc Med* (2021) 8:698725. doi: 10.3389/fcvm.2021.698725

24. Mi D, Li Z, Gu H, Jiang Y, Zhao X, Wang Y, et al. Stress hyperglycemia is associated with in-hospital mortality in patients with diabetes and acute ischemic stroke. *CNS Neurosci Ther* (2022) 28(3):372–81. doi: 10.1111/cns.13764

25. Yuan C, Chen S, Ruan Y, Liu Y, Cheng H, Zeng Y, et al. The stress hyperglycemia ratio is associated with hemorrhagic transformation in patients with acute ischemic stroke. *Clin Interv Aging* (2021) 16:431–42. doi: 10.2147/CIA.S280808

26. Liao Y, Zhang R, Shi S, Zhao Y, He Y, Liao L, et al. Triglyceride-glucose index linked to all-cause mortality in critically ill patients: A cohort of 3026 patients. *Cardiovasc Diabetol* (2022) 21(1):128. doi: 10.1186/s12933-022-01563-z

27. Wang L, Zhang Z, Hu T. Effectiveness of LODS, OASIS, and SAPS II to predict in-hospital mortality for intensive care patients with ST elevation myocardial infarction. *Sci Rep* (2021) 11(1):23887. doi: 10.1038/s41598-021-03397-3

28. Hu T, Lv H, Jiang Y. The association between four scoring systems and 30-day mortality among intensive care patients with sepsis: A cohort study. *Sci Rep* (2021) 11(1):11214. doi: 10.1038/s41598-021-90806-2

29. Johnson AE, Kramer AA, Clifford GD. A new severity of illness scale using a subset of acute physiology and chronic health evaluation data elements shows comparable predictive accuracy. *Crit Care Med* (2013) 41(7):1711–8. doi: 10.1097/CCM.0b013e31828a24fe

30. Kerby JD, Griffin RL, MacLennan P, Rue LW 3rd. Stress-induced hyperglycemia, not diabetic hyperglycemia, is associated with higher mortality in trauma. *Ann Surg* (2012) 256(3):446–52. doi: 10.1097/SLA.0b013e3182654549

31. Salazar J, Angarita L, Morillo V, Navarro C, Martínez MS, Chacín M, et al. Microbiota and diabetes mellitus: Role of lipid mediators. *Nutrients* (2020) 12(10). doi: 10.3390/nu12103039

32. Bahadoran Z, Mirmiran P, Ghasemi A. Role of nitric oxide in insulin secretion and glucose metabolism. *Trends Endocrinol Metab* (2020) 31(2):118–30. doi: 10.1016/j.tem.2019.10.001

33. Ingels C, Vanhorebeek I, Van den Berghe G. Glucose homeostasis, nutrition and infections during critical illness. *Clin Microbiol Infect* (2018) 24(1):10–5. doi: 10.1016/j.cmi.2016.12.033

34. Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. *J Am Coll Cardiol* (2009) 53(5 Suppl):S14–20. doi: 10.1016/j.jacc.2008.10.038